Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Thomas, Douglas D. / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


IMPACT FACTOR 2016: 3.273

CiteScore 2016: 3.01

SCImago Journal Rank (SJR) 2016: 1.679
Source Normalized Impact per Paper (SNIP) 2016: 0.800

Online
ISSN
1437-4315
See all formats and pricing
More options …
Volume 389, Issue 5 (May 2008)

Issues

Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection

May Young Lin
  • 1Department of Immunohaematology and Blood Transfusion, Leiden University Medical Centre, NL-2300 RC Leiden, The Netherlands and Department of Infectious Diseases, Leiden University Medical Centre, NL-2300 RC Leiden, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tom H.M. Ottenhoff
  • 2Department of Immunohaematology and Blood Transfusion, Leiden University Medical Centre, NL-2300 RC Leiden, The Netherlands and Department of Infectious Diseases, Leiden University Medical Centre, NL-2300 RC Leiden, The Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2008-03-27 | DOI: https://doi.org/10.1515/BC.2008.057

Abstract

Mycobacterium tuberculosis is one of the worlds' most successful and sophisticated pathogens. It is estimated that over 2 billion people today harbour latent M. tuberculosis infection without any clinical symptoms. As most new cases of active tuberculosis (TB) arise from this (growing) number of latently infected individuals, urgent measures to control TB reactivation are required, including post-exposure/therapeutic vaccines. The current bacille Calmette-Guérin (BCG) vaccine and all new generation TB vaccines being developed and tested are essentially designed as prophylactic vaccines. Unfortunately, these vaccines are unlikely to be effective in individuals already latently infected with M. tuberculosis. Here, we argue that detailed analysis of M. tuberculosis genes that are switched on predominantly during latent stage infection may lead to the identification of new antigenic targets for anti-TB strategies. We will describe essential host-pathogen interactions in TB with particular emphasis on TB latency and persistent infection. Subsequently, we will focus on novel groups of late-stage specific genes, encoded amongst others by the M. tuberculosis dormancy (dosR) regulon, and summarise recent studies describing human T-cell recognition of these dormancy antigens in relation to (latent) M. tuberculosis infection. We will discuss the possible relevance of these new classes of antigens for vaccine development against TB.

Keywords: bacille Calmette-Guérin (BCG); dormancy; dosR regulon; M. bovis persistence; post-exposure vaccines; T-cells

About the article

Corresponding author


Published Online: 2008-03-27

Published in Print: 2008-05-01


Citation Information: Biological Chemistry, ISSN (Online) 14374315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2008.057.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Gareth Prosser, Julius Brandenburg, Norbert Reiling, Clifton Earl Barry, Robert J. Wilkinson, and Katalin A. Wilkinson
Microbes and Infection, 2017, Volume 19, Number 3, Page 177
[2]
Dolapo O. Awoniyi, Andrea Teuchert, Jayne S. Sutherland, Harriet Mayanja-Kizza, Rawleigh Howe, Adane Mihret, Andre G. Loxton, Jacob Sheehama, Desta Kassa, Amelia C. Crampin, Hazel M. Dockrell, Martin Kidd, Ida Rosenkrands, Annemieke Geluk, Tom H.M. Ottenhoff, P.L.A.M. Corstjens, Novel N. Chegou, Gerhard Walzl, Gerhard Walzl, Novel N. Chegou, Magdalena Kriel, Gian van der Spuy, Andre G. Loxton, Kim Stanley, Stephanus Malherbe, Shirley Mcanda, Belinda Kriel, Khutso G. Phalane, Paulin Essone, Jayne S. Sutherland, Olumuyiwa Owolabi, Abdou Sillah, Joseph Mendy, Awa Gindeh, Simon Donkor, Toyin Togun, Martin Ota, Amelia C. Crampin, Felanji Simukonda, Alemayehu Amberbir, Femia Chilongo, Rein Houben, Desta Kassa, Atsbeha Gebrezgeabher, Getnet Mesfin, Yohannes Belay, Gebremedhin Gebremichael, Yodit Alemayehu, Marieta van der Vyver, Faustina N. Amutenya, Josefina N. Nelongo, Lidia Monye, Jacob A. Sheehama, Scholastica Iipinge, Harriet Mayanja-Kizza, Ann Ritah Namuganga, Grace Muzanye, Mary Nsereko, Pierre Peters, Rawleigh Howe, Adane Mihret, Yonas Bekele, Bamlak Tessema, Lawrence Yamuah, Tom H.M. Ottenhoff, Annemieke Geluk, Kees Franken, Paul L.A.M. Corstjens, Elisa M. Tjon Kon Fat, Claudia J. de Dood, Jolien J. van der Ploeg-van Schip, Ida Rosenkrands, Claus Aagaard, Stefan H.E. Kaufmann, Maria M. Esterhuyse, Jacqueline M. Cliff, and Hazel M. Dockrell
Journal of Infection, 2016, Volume 73, Number 3, Page 219
[3]
Jae-Min Yuk and Eun-Kyeong Jo
Clinical and Experimental Vaccine Research, 2014, Volume 3, Number 2, Page 155
[4]
Annemieke Geluk, Krista E. van Meijgaarden, Simone A. Joosten, Susanna Commandeur, and Tom H. M. Ottenhoff
Frontiers in Immunology, 2014, Volume 5
[5]
Stefan HE Kaufmann, Gregory Hussey, and Paul-Henri Lambert
The Lancet, 2010, Volume 375, Number 9731, Page 2110
[6]
M. Kohns, J. Seyfarth, D. Schramm, E. Mayatepek, and M. Jacobsen
Monatsschrift Kinderheilkunde, 2013, Volume 161, Number 8, Page 697
[7]
Stefan H.E. Kaufmann
Immunity, 2010, Volume 33, Number 4, Page 567
[8]
Juan Pablo Isaza, Camilo Duque, Verónica Gomez, Jaime Robledo, Luis F. Barrera, and Juan F. Alzate
FEMS Microbiology Letters, 2012, Volume 330, Number 2, Page 113
[9]
Raija K Ahmed, Zoyia Rohava, Kithiganahalli N Balaji, Sven E Hoffner, Hans Gaines, Isabelle Magalhaes, Alimuddin Zumla, Alena Skrahina, and Markus J Maeurer
BMC Infectious Diseases, 2012, Volume 12, Number 1
[10]
Novel N Chegou, Gillian F Black, Andre G Loxton, Kim Stanley, Paulin N Essone, Michel R Klein, Shreemanta K Parida, Stefan HE Kaufmann, T Mark Doherty, Annemieke H Friggen, Kees L Franken, Tom H Ottenhoff, and Gerhard Walzl
BMC Infectious Diseases, 2012, Volume 12, Number 1
[11]
Wiebren Santema, Victor Rutten, and Ad Koets
Veterinary Quarterly, 2011, Volume 31, Number 4, Page 183
[12]
Jim Sun, Alice Lau, Xuetao Wang, Ting-Yu Angela Liao, Amina Zoubeidi, and Zakaria Hmama
Plasmid, 2009, Volume 62, Number 3, Page 158
[13]
Stephen T. Reece, Ali Nasser-Eddine, Jes Dietrich, Maik Stein, Ulrike Zedler, Sandra Schommer-Leitner, Tom H.M. Ottenhoff, Peter Andersen, and Stefan H.E. Kaufmann
Vaccine, 2011, Volume 29, Number 47, Page 8740
[14]
Paul-Henri Lambert, Tony Hawkridge, and Willem A. Hanekom
Clinics in Chest Medicine, 2009, Volume 30, Number 4, Page 811
[15]
Shivsharan Kharatmal, Sarbjit Singh Jhamb, and Prati Pal Singh
Journal of Microbiological Methods, 2009, Volume 78, Number 2, Page 161
[16]
Daniel S. Korbel, Bianca E. Schneider, and Ulrich E. Schaible
Microbes and Infection, 2008, Volume 10, Number 9, Page 995
[17]
Hannah P. Gideon and JoAnne L. Flynn
Immunologic Research, 2011, Volume 50, Number 2-3, Page 202
[18]
Maytal Bivas-Benita, May Young Lin, Suzanne M. Bal, Krista E. van Meijgaarden, Kees L.M.C. Franken, Annemieke H. Friggen, Hans E. Junginger, Gerrit Borchard, Michèl R. Klein, and Tom H.M. Ottenhoff
Vaccine, 2009, Volume 27, Number 30, Page 4010
[19]
Angela M Minassian and Helen McShane
Expert Review of Respiratory Medicine, 2008, Volume 2, Number 6, Page 721
[20]
Aw Kang Lie Darius, Neo Jia Ling, and Uttamchandani Mahesh
Molecular BioSystems, 2010, Volume 6, Number 5, Page 792
[21]
N. Talat, F. Shahid, G. Dawood, and R. Hussain
Scandinavian Journal of Immunology, 2009, Volume 69, Number 6, Page 537

Comments (0)

Please log in or register to comment.
Log in